This report is a PAID ADVERTISEMENT from Oilprice.com
Someone dies of a stroke every 4 minutes in the United States. Globally, 15 million people suffer a stroke every year. It’s debilitating physically and financially—but one little-known company has developed a medical device that hopes to challenge that deadly statistic.
It’s been quietly developing this new technology for 10 years. Now it’s released updated preliminary clinical trial results, and signed a manufacturing deal which could make a significant impact in the medical device industry.
After a decade of painstaking development, we’re now nearing the end of the long road to validation, and for investors who understand this industry, this could be the critical juncture.
The little-known company is CVR Medical (TSX:CVM.V; OTC:CRRVF), and its potentially life-saving device is the Carotid Stenotic Scan (CSS)–a technology designed to detect stenosis within arteries, or Ischemia, which is the leading indicator of strokes.
Of the 15 million people who suffer stroke every year, some 6 million are killed, while 5 million are rendered permanently disabled, according to the World Heart Foundation.
But there has been no cost-effective way to screen for Ischemia.
So, when a biotech company offers a potential solution to help prevent the second-leading cause of death in the world–and then releases positive preliminary clinical trial results, investors listen.
Now it’s hoping to charge out of the gate and take the market by storm once it manages to gain FDA market clearance.
In the meantime, the catalysts are really lining up:
On 7 September, CVR released updated results from its preliminary clinical trial that showed forward progress for the medical device, which we’ve been watching closely for some time. You can view the results from Thomas Jefferson University HERE.
And a few weeks prior, they announced another landmark achievement when they signed a letter of Click to see the original article